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 ABSTRACT  
OBJECTIVES 
Heterogeneity in outcomes measured across trials of glucose lowering interventions for 
people with type 2 diabetes impacts on the ability to compare findings and may mean that the 
results have little importance to health care professionals and the patients that they care for. 
The SCORE-IT study has addressed this issue by establishing consensus on the most 
important outcomes for non-surgical interventions for hyperglycaemia in type 2 diabetes.  
RESEARCH DESIGN AND METHODS 
A comprehensive list of outcomes was developed from registered clinical trials, online 
patient resources, the qualitative literature and long-term studies in the field.  This list was 
then scored in a two round online Delphi survey completed by healthcare professionals, 
people with type 2 diabetes, researchers in the field and healthcare policymakers. The results 
of this online Delphi were discussed and ratified at a face to face consensus meeting. 
RESULTS 
173 people completed both rounds of the online survey (116 people with type 2 diabetes, 37 
healthcare professionals, 14 researchers and 6 policy makers), 20 of these attended the 
consensus meeting (13 people with type 2 diabetes and seven healthcare professionals). 
Consensus was reached on 18 core outcomes across five domains, that include outcomes 
related to diabetes care, quality of life and long term diabetes-related complications.  
CONCLUSIONS 
Implementation of the core outcome set in future trials will ensure that outcomes of 
importance to all stakeholders are measured and reported, enhancing the relevance of trial 
findings and facilitating the comparison of results across trials.    
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Significance of this study 
What is already known about this subject?  
A systematic review of active clinical trials registered with clinicaltrials.gov identified marked 
heterogeneity in the outcomes measured in trials of glucose lowering interventions for people with 
type 2 diabetes.  This inconsistency in outcomes impacts on the ability to compare findings and may 
mean  that the results have little importance to health care professionals and the patients that they 
care 
What are the new findings?  
Eighteen outcomes have been included in the SCORE-IT core outcome set, across five domains, that 
reflect outcomes related to diabetes care, quality of life and diabetes-related complications.  This 
core outcome set has been developed with input from all stakeholders including people with type 2 
diabetes, healthcare professionals, researchers in the field and healthcare policymakers/payers and 
has ensured that all participants had an equal voice when deciding the most important outcomes 
How might these results change the focus of research or clinical practice? 
Implementation of the SCORE-IT core outcome set in future clinical trials, of glucose lowering 
interventions, will increase the relevance of research to all stakeholders and will allow results from 
different trials to be more easily compared and combined. This increased potential for meta-analysis 
will enable new, effective treatments to be made available to people with type 2 diabetes more 
quickly.  
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 BACKGROUND 
Type 2 diabetes is a global pandemic. Current estimates indicate that 623 million people aged 
20-79 will be affected by diabetes by 2045 with the majority of these cases being type 2 
diabetes (1-3). 
Treatment for type 2 diabetes is targeted at the hyperglycaemia arising due to a resistance to 
insulin action and an inadequate insulin secretory response (4, 5). Lifestyle changes or 
pharmacotherapy aim to control blood glucose levels and avoid hyperglycaemia and 
associated long term complications (6, 7)(8-12) and these may also be supplemented with 
bariatric surgical intervention (13). 
A recent review of open (actively recruiting or in follow-up period), phase 3 and 4 trials 
registered with clinical trials.gov identified considerable variation in the outcomes measured 
and reported for glucose lowering therapies in people with type 2 diabetes (14). This 
variation may impact on the ability to compare studies and hinder evidence synthesis 
contributing to waste in research (15). Furthermore, of the outcomes measured in the 
included trials only 10% represented patient reported outcomes. It is possible to address these 
issues and to increase the relevance of research by developing a core outcome set (COS), 
representing an agreed standardised set of outcomes that should be measured and reported in 
all trials for a specific clinical area (16).  To date only two studies have investigated 
important outcomes for diabetes. Byrne et al have developed a COS for young adults with 
type 1 diabetes (17) and  Murad et al (18) explored  outcomes  important to patients with 
diabetes using a single item on a questionnaire that ranked a list of ten outcomes.   
The aim of the SCORE-IT study was to address this gap in outcomes research and develop a 
COS for use in clinical trials of non-surgical therapeutic interventions for the treatment of 
hyperglycaemia in adults with type 2 diabetes that includes input from all stakeholders.  
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 METHODS 
Study Overview 
The development of the COS involved three stages (figure 1): (1) the generation of a long-list 
of outcomes for use in an online Delphi, (2) a two round online Delphi survey with key 
stakeholders and (3) a face to face consensus meeting to discuss the results of the Delphi 
survey and agree the COS.  Methods for each step are described briefly below. A study 
protocol, systematic review and qualitative review describing methods in full have been 
published elsewhere (19-21) 
Outcome list generation 
The list of outcomes was generated from a number of sources(19): a systematic review of 
open trials registered with clinical trials.gov , a rapid review of the qualitative literature and 
extraction of outcomes from patient experiences reported on HealthTalk Online  (22) The 
detailed search strategies for clinicaltrials.gov and for the qualitative review have been 
published elsewhere (14, 21). In addition to these sources outcomes were extracted from 
transcripts of video clips of adults aged 18 years and over with type 2 diabetes who shared 
their experience on the  publically available HealthTalk online website (22).  The SSC also 
provided a list of long term cardiovascular outcome studies in people with type 2 diabetes 
from which outcomes were extracted (23-34). Outcomes were extracted verbatim, for each 
source,  before being grouped using a standardised outcome name and categorised according 
to the taxonomy of Dodd et al (35).  The list was cross checked against outcomes and 
domains included in the patient reported outcome measures (PROMs) identified by Reaney et 
al (36) , the BIRO common dataset for diabetes (37) and relevant Cochrane reviews. To 
identify relevant reviews the Cochrane database of systematic reviews was searched for “type 
2 diabetes” in the “title”, “abstract” and “key words” fields. The resulting list of outcomes 
was reviewed by the Study Steering Committee (SSC) and outcomes further grouped or 
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 excluded if measured in a single study and/or considered to be of limited clinical importance 
to glucose lowering interventions. Each outcome was written using plain language and 
feedback sought from the public contributor members of the SSC on the acceptability and 
their understanding of the wording used. 
 Online Delphi survey of stakeholders 
The long list of outcomes was used to populate an online Delphi survey, delivered using the 
DelphiManager platform (38). Participants were invited from four key stakeholder groups: 
people with type 2 diabetes and their carers; healthcare professionals involved in delivering 
care for people with type 2 diabetes; researchers in the field and healthcare 
policymakers/payers. Invitations to participate were shared with national and international 
patient and professional organisations who were asked to distribute the invitations to their 
membership (supplementary file 1). We also approached the lead contact of the studies 
included in the clinicaltrials.gov review, authors of relevant Cochrane reviews, researchers in 
receipt of funding from a large UK Diabetes charity, programme leads at the National 
Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) and UK based Diabetes Research centres. Finally, health professionals in the UK 
were contacted via the Wilmington’s UK database of health professionals. Policymakers were 
identified through the INAHTA members list and organisations approached individually. 
The Delphi process was completed using two rounds (termed R1 and R2). In each round 
participants were presented with the list of outcomes and asked to score each outcome on 
how important it was to include it in the COS using a nine point Likert scale presented in the 
format 1 to 9, with 1 to 3 labelled ‘not important’, 4 to 6 labelled ‘important but not critical’ 
and 7 to 9 labelled ‘critically important’(39). At the end of R1 participants were invited to 
submit additional outcomes, these outcomes were reviewed by the SSC and any suggestions 
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 representing a new outcome added to the list to be scored in round 2. Outcomes were not 
removed from the list between R1 and R2.  
During R2 participants were shown the distribution of scores for each stakeholder group for 
each outcome together with their own score from round 1 and asked to score the outcome 
again, using the same 1-9 Likert scale,  taking this information into consideration.  
 
Consensus Meeting 
A face to face consensus meeting was held in Liverpool, UK and the results of the online 
Delphi survey presented. Participants who had completed both R1 and R2 of the Delphi were 
invited to attend. Prior to the meeting participants received a copy of their scores from the 
online survey and  a consensus matrix detailing the results of R2 by stakeholder group 
(supplementary file 2 ) and which outcomes had reached the predefined definition of 
consensus “in” or consensus “out” (table 1).  
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Table 1. Definition of consensus 
Consensus 
Classification 
Description Definition 
Consensus in Consensus that outcome should be 
included in the core outcome set 
70% or more participants in each 
stakeholder group scoring as 7-9 AND <15% 
participants in each stakeholder group 
scoring as 1-3 
Consensus out Consensus that outcome should 
not be included in the core 
outcomes set 
50% or fewer participants scoring 7-9 in 
each stakeholder group. 
No consensus  Uncertainty about importance of 
outcome 
Anything else 
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 The meeting was chaired by an independent non-clinical researcher with expertise in COS 
development methodology.  Outcomes that had reached consensus “in” after R2 in all four 
stakeholder groups were presented first followed by outcomes that had reached consensus 
“out” after R2 in all four stakeholder groups. Meeting participants were asked if they 
disagreed with the inclusion or exclusion of these items from the COS respectively.  All 
outcomes with two or more stakeholder groups reaching consensus “in” were discussed, 
outcomes with one stakeholder group reaching consensus “in” were shown to meeting 
participants and participants asked if any of these should be discussed. Outcomes with no 
consensus and no group scoring consensus “in” were not discussed.  
Views for and against inclusion in the COS were sought by the meeting chair who also 
ensured that participants had equal opportunity to comment prior to voting. Voting took place 
anonymously using TurningPoint© software and handsets (Turning Technologies LLC, 
Youngstown, USA). Following voting the results were displayed to participants by 
stakeholder group. For the purpose of the consensus meeting stakeholder groups were 
condensed to healthcare professionals (this group included researchers in the field who also 
had a clinical role) and people with type 2 diabetes. Healthcare policymakers were present to 
provide their perspective and contribute to the discussions. The definition of consensus used 
in the Delphi survey (table 1) was applied with both groups required to reach the definition of 
consensus “in” for the outcome to be included in the COS. The final COS was presented at 
the end of the meeting and also included in a summary sent to participants after the meeting.  
Other analyses 
Attrition bias between R1 and R2 of the online Delphi was assessed by comparing the 
distribution of mean R1 scores for participants completing R1 only and participants 
completing both R1 and R2.  Satisfaction with the consensus meeting process, organisation 
and outcome was assessed using a questionnaire (supplementary file 3). 
SCORE-IT Final report V1.0  Page 10 of 30 
 Ethical approval, study registration and study oversight 
The SCORE-IT study was prospectively registered with the COMET Initiative (Core 
Outcome Measures in Effectiveness Trials) (40). Ethical approval was obtained from the 
University of Liverpool Research Ethics Committee prior to undertaking the consensus 
methods (online Delphi and consensus meeting) ref: 3306. The SSC composition has been 
described previously (19). The SCORE-IT study is reported in line with the Core Outcome 
Set – Standards for Reporting (COS-STAR) reporting guidance (41). 
 
RESULTS 
An overview of the SCORE-IT COS development process and final COS is shown in figure 
1. The final COS includes 18 outcomes across five domains (table 2).
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Table 2. Outcomes included in the SCORE-IT core Outcome Set. 
 
 
Outcome Domain 
Glycaemic control - how well someone's blood glucose is controlled. Physiological/ 
clinical 
Global quality of life - someone's overall quality of life including physical, 
mental and social wellbeing. 
Life impact 
Activities of daily living - being able to complete usual everyday tasks and 
activities including those related to personal care; house hold tasks or 
community based tasks. 
Life impact 
Body weight - how much someone weighs. Physiological/ 
clinical 
Kidney function - how well someone's kidneys are working. Physiological/ 
clinical 
Hyperglycaemia - how often someone has high blood glucose. Physiological/ 
clinical 
Hypoglycaemia - how often someone has low blood glucose levels. Physiological/ 
clinical 
Visual deterioration or blindness - if someone's eyesight gets worse or if 
they have loss of vision  including blindness. 
Physiological/ 
clinical 
Neuropathy - damage to the nerves caused by high glucose. This can lead to 
tingling and pain or numbness in the feet or legs. It can also affect bowel 
control; stomach emptying and sexual function. 
Physiological/ 
clinical 
Having gangrene or having an amputation of the leg, foot or toe. Physiological/ 
clinical 
Nonfatal myocardial infarction - having a heart attack that is not fatal. Physiological/ 
clinical 
Heart failure Physiological/ 
clinical 
Cerebrovascular disease - including stroke, subarachnoid haemorrhage, 
transient ischaemic attack and vascular dementia. 
events 
How often someone is admitted to hospital because of their diabetes. Resource use 
Hyperglycaemic emergencies (to include diabetic ketoacidosis and 
hyperosmolar hyperglycaemic state). 
Physiological/cli
nical 
Side effects of treatment- any unwanted effects of the treatment. Adverse events 
Overall survival - how long someone lives. Death  
Death from a diabetes related cause such as heart disease. Death  
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 Development of the long list of outcomes 
The systematic review of clinical trials and the rapid review of qualitative studies have been 
presented in detail elsewhere (14). The review of clinical trials yielded 1444 individual 
outcomes and the qualitative review 474. These were combined with 409 outcomes from the 
long term cardiovascular outcome studies and 232 outcomes identified from HealthTalk 
Online.  The resulting 2560 outcomes were reviewed and outcome names standardised to 
give 223 outcomes. These 223 outcomes were reviewed against the remaining data sources. 
One additional outcome “hyperosmolar hyperglycaemic state” was identified from the review 
of outcomes used in Cochrane reviews and added to the long list. No further outcomes were 
identified from the BIRO dataset(37) or review of PROMs (36).  
The 223 outcomes were mapped onto a 38 category system and grouped under five domains 
(mortality n=5, life impact n = 67, physiological/clinical n=127,resource use n= 22 and 
adverse events n=2)(35). These outcomes were then presented to the SSC and after 
discussion 64 outcomes (supplementary file 4) were taken forward to the online Delphi.  
Online Delphi process 
One hundred and seventy three participants completed both R1 and R2 of the online survey. 
Participants comprised of 37 healthcare professionals, 116 people with type 2 diabetes or 
their carers, 14 researchers in the field and 6 healthcare policymakers (Table 3).
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 N(%) 
Healthcare professionals 37 (100%) 
Occupation  
Consultant 17 (21%) 
Dietitian 7 (9%) 
General practitioner 18 (23%) 
Pharmacist  2 (3%) 
Specialist nurse/practice nurse 36 (45%) 
  
Country of residence  
Austria 1 (3%) 
Germany 1 (3%) 
Greece 1 (3%) 
India 1 (3%) 
Mexico 1 (3%) 
Singapore 1 (3%) 
Switzerland 1 (3%) 
United Kingdom 30 (81%) 
  
People with type 2 diabetes and 
their carers 
116 (100%) 
Age (years)  
30-39 3 (3%) 
40-49 8 (7%) 
50-59 19 (16%) 
60-69 55 (47%) 
70-79 29 (25%) 
>80 2 (2%) 
Country of residence  
Greece 1 (1%) 
UK 115 (99%) 
  
Researchers in the field 14 (100%) 
Country of residence  
Malaysia 2 (14%) 
Singapore 1 (7%) 
South Africa 1 (7%) 
United Kingdom 9 (64%) 
Not reported 1 (7%) 
  
Healthcare policymakers/payers 6 (100%) 
Country of residence  
Argentina 1 17%) 
Australia 1 (17%) 
Austria 1 (17%) 
Canada 1 (17%) 
Germany 1 (17%) 
  Sweden 1 (17%) 
 
Table 3. Characteristics of Delphi Participants completing R1 and R2   
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 At the end of R1 ten outcomes met the predefined criteria for inclusion in the COS across all 
four stakeholder groups. Fifty one responses were received to the free text question asking 
participants if there were any additional outcomes they would like to add. These outcomes 
were reviewed by the SSC and one outcome “gut microbiome - the type/number of bacteria 
in someone's digestive tract” was added and scored by participants in R2.  A further three 
outcomes (activities of daily living, satisfaction with treatment and care and emotional 
wellbeing) were modified based on the free text response to clarify the outcome.  
At the end of R2 of the Delphi nine outcomes had reached consensus, for inclusion in the 
COS, across all four stakeholder groups and nine outcomes had reached the definition for 
exclusion from the COS (supplementary file 2 ).   
Six outcomes reached the definition of “consensus in” in both R1 and  R2 and have been 
included in the final COS.    
The overall attrition rate between R1 and R2 was 25%, with the highest attrition rate 
observed for specialist/practice nurses (table 3). 
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Stakeholder Number 
registered (% of 
total 
registrations) 
Withdrawn 
prior to 
completing 
R1 
Withdrawn 
after R1 ad 
before R2 
Completed R1 
n (%of 
registrations 
minus 
withdrawals 
before R1) 
Completed 
R2 n (% of 
R1) 
Healthcare 
professionals 
80 (25%) 0 0 56 (70%) 37 (66%) 
Consultant 17 (5%) 0 0 10 (59%) 8 (80%) 
Dietitian 7 (2%) 0  6 (86%) 5 (83%) 
General 
Practitioner 
18 (6%) 0 0 13 (72%) 8 (62%) 
Pharmacist  2 (1%) 0 0 2 (100%) 2 (100%) 
Specialist/practice 
nurse 
36 (11%) 0 0 25 (69%) 14 (56%) 
      
      
Researchers in the 
field 
20 (6%) 0 1 17 (85%) 14 (88%) 
Policy 
makers/payers 
9 (3%) 0 0 7 (78%) 6 (86%) 
      
People with type 2 
diabetes or their 
careres 
211 (66%) 5 2 153 (74%) 116 (77%) 
Carer 5 (2%) 0 0 3 (60%) 1 (33%) 
Patient 206 (64%) 5 2 150 (75%) 115 (78%) 
      
Total  320 5 3 233 (74%) 173 (75%) 
 
 
Table 4.  Attrition rates between rounds
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 The impact of attrition between rounds was assessed by comparing the average R1 scores of 1 
those who did not complete R2 against the distribution of scores for those completing both 2 
R1 and R2. Overall the distribution of average scores of those who did not complete R2 was 3 
similar to those completing both R1 and R2 for all stakeholder groups suggesting that 4 
attrition bias was not present between rounds (supplementary file 5).  5 
Consensus Meeting 6 
Twenty participants attended the consensus meeting (7 healthcare professionals and 13 7 
people with type 2 diabetes); in addition to the 20 voting participants there were 3 healthcare 8 
policymakers/payers who contributed to discussion along with members of the study steering 9 
committee. In the consensus meeting a further nine outcomes met the definition for inclusion 10 
in the COS in addition to the nine outcomes that had reached the definition of consensus for 11 
inclusion at the end of R2 of the Delphi (supplementary file 6). Of these outcomes, eight 12 
required further discussion by the SSC at a follow up teleconference (supplementary file 7). 13 
In addition to wording changes one outcome  “diabetic ketoacidosis” was amended to 14 
“hyperglycaemic emergencies (to include diabetic ketoacidosis and hyperosmolar 15 
hyperglycaemic state)” The  SSC also reflected on the outcomes  “hyperglycaemia”, how this 16 
had been  interpreted by Delphi participants and that further discussion/think aloud work 17 
prior to launching the Delphi may have been needed.  Finally, the SSC discussed the 18 
comment raised at the consensus meeting to add  “prolongation of hospital stay” to the 19 
outcome “how often someone is admitted to hospital because of their diabetes”. All agreed 20 
that this was a separate outcome that had not been scored or added in the Delphi but is an 21 
important point for future discussion.  22 
Feedback forms from the meeting were completed by four (57%) healthcare professionals 23 
and 13 (92%) people with type 2 diabetes. All participants were satisfied with the way the 24 
meeting was facilitated, felt able to contribute to the meeting and felt comfortable expressing 25 
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 their views. In terms of the consensus meeting producing a fair result, one health professional 26 
felt that voting may have been influenced by a dominant participant and one person with type 27 
2 diabetes neither agreed nor disagreed with the statement.   28 
DISCUSSION  29 
The SCORE-IT study has developed patient and health professional consensus on outcomes 30 
for trials of the treatment of hyperglycaemia in people with type 2 diabetes. The process to 31 
achieve consensus has ensured that all stakeholders including people with type 2 diabetes, 32 
healthcare professionals, researchers in the field and healthcare policymakers/payers have 33 
been able to contribute to the final COS. We recommend that future trials of interventions to 34 
treat hyperglycaemia in people with type 2 diabetes use the SCORE-IT COS. This COS does 35 
not prevent other outcomes being measured, as appropriate to the intervention, but rather 36 
represents the minimum that should be measured.   37 
Particular strengths of the SCORE-IT COS include the use of methods meeting the COS-38 
STAD recommendations (42), published in a study protocol prior to undertaking the study 39 
(19). This study has also engaged multiple stakeholder groups including health professionals 40 
and people with type 2 diabetes to achieve consensus on the most important outcomes. Only 41 
3% of COS to date have included input from healthcare policymakers (43), the inclusion of 42 
policymakers in the present study has ensured that important outcomes used when evaluating 43 
the available evidence and making decisions are taken into consideration in the final COS. In 44 
the SCORE-IT study members of the International Network of Agencies for Health 45 
Technology Assessment (INAHTA) were approached with an invitation to take part (44). Of 46 
the 50 members, six (12%) completed R1 and R2 suggesting that further work is needed to 47 
engage with HTA organisations to facilitate the contribution of this stakeholder group to COS 48 
development.  49 
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 Although this study has had some international input, engagement both in the UK and on an 50 
international level was challenging with only one patient and a fifth of healthcare 51 
professionals and researchers combined based outside of the UK. We sought to improve 52 
international input from people with type 2 diabetes through engagement with patient 53 
organisations and translation of the Delphi into the appropriate local language. However, 54 
despite Polish and Brazilian Portuguese versions being distributed, via  direct email to 55 
members of patient organisations, participation was low with only one person completing R1 56 
of the Delphi in Polish . Choosing appropriate outcomes to measure is a top methodological 57 
priority for trialists working in low and middle income countries (LMICs)  (45). A recent 58 
review found the number of COS being developed in some LMICs has increased (43) yet the 59 
number of participants in each COS, the methods of engagement and source of recruitment 60 
have yet to be explored. Further work is warranted in the field of COS research more 61 
generally on how best to engage stakeholders and facilitate participation nationally, 62 
internationally and particularly in countries where representation in the COS development 63 
process is low. For the SCORE-IT COS it will be important to evaluate the acceptability of 64 
the current COS to patients and professionals in other countries, particularly where healthcare 65 
systems differ to that in the UK.   66 
The SCORE-IT COS is specific for type 2 diabetes yet there is overlap with outcomes of 67 
importance to young adults with type 1 diabetes identified by  Byrne et al (17). Of the eight 68 
outcomes in their COS all three outcomes that are physiological/clinical are included in the 69 
current SCORE-IT COS  (17). Quality of life is also common across the two COS although, 70 
in the study by Byrne et al, this was amended to “diabetes related quality of life” in response 71 
to discussion at the consensus meeting.  Other outcomes included in the COS for young 72 
adults with type 1 diabetes were included in the long list of outcomes scored in R1 of the 73 
present study yet these outcomes did not reach the definition of consensus “in”. Self-74 
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 management behaviour, specifically “Diabetes self-care activities…”” was discussed further 75 
at the consensus meeting but did not reach the definition of consensus for inclusion in the 76 
COS .  The SCORE-IT COS includes additional outcomes that reflect complications of 77 
hyperglycaemia, that were not included in the COS developed by Byrne et al suggesting that, 78 
whilst there are some similarities, the priorities of the stakeholders vary depending on the 79 
type of diabetes and the age group of participants. 80 
Murad et al included participants with both type 1 (5%) and type 2 (93%) in a survey to 81 
identify participants top five outcomes from a list of ten(18).  All ten of the outcomes ranked 82 
were included in the current Delphi survey and all, with the exception of need for 83 
photocoagulation, scored in the present study as retinopathy, were included in the current 84 
COS with HbA1c and end stage renal disease included in the “glycaemic control” and 85 
“kidney function” outcomes respectively.  The list of outcomes used by Murad et al was 86 
generated from a panel of eight patients and ranked by patients only.  Our approach to the 87 
development of the outcomes list and engagement of people with type 2 diabetes,  healthcare 88 
professionals and researchers has identified an additional ten outcomes, including outcomes 89 
within the life impact domain (quality of life and activities of daily living), that are important 90 
to all stakeholders.  91 
The International Consortium for Health Outcomes Measurement (ICHOM) have recently  92 
reported a standard set for diabetes in adults(46). The development of this standard set has 93 
included international input from 26 experts (3 patients and 23 clinicians) and includes 26 94 
outcomes.  Fifty four percent of the ICHOM standard set is reflected in the SCORE-IT COS 95 
with some subtle differences. Most notably the life impact outcomes between the two 96 
outcome sets differ. Psychological wellbeing, diabetes distress and depression are included in 97 
ICHOM whilst these outcomes, scored collectively in SCORE-IT as “Emotional wellbeing“,   98 
did not reach the definition of “consensus in” in any round of the Delphi survey.  Instead 99 
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 participants of the SCORE-IT study rated “global quality of life” and “activities of daily 100 
living” as the most important life impact outcomes.  Two outcomes in the ICHOM standard 101 
set “periodontal health” and “emergency room utilisation” were not included in the SCORE-102 
IT Delphi list of outcomes. Periodontal  health was not measured/identified from any of the 103 
sources used to generate the long list of outcomes  whilst the need to attend the emergency 104 
room was identified in the systematic review but measured only in a single study and not 105 
taken forward to the Delphi survey. Neither outcome was added to the list by Delphi 106 
participants completing R1 of the Delphi survey.  107 
Whilst there is substantial overlap between the ICHOM standard set and the SCORE-IT COS 108 
differences may reflect the scope of the projects, clinical practice versus clinical trials 109 
respectively,  and may also be influenced by the methods used and the type, number and 110 
geographical location of the stakeholders involved. Nevertheless the overlap between studies 111 
is positive and if outcomes are captured routinely in clinical practice then this may help 112 
improve the efficiency of clinical trials and reduce the burden to trial participants.  113 
 114 
Conclusions 115 
The COS developed in the SCORE-IT study can be applied to future clinical trials of non-116 
surgical interventions to treat hyperglycaemia and its use will allow comparisons to take 117 
place across trials, thereby reducing waste in research. The next steps will include seeking 118 
consensus on how these outcomes should be measured and to provide this guidance to 119 
researchers.  120 
 121 
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Figure 1: Core Outcome Set Development Overview 
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